[go: up one dir, main page]

MX2010007023A - Agonistas del receptor glucocorticoide sustituido de c20-c21. - Google Patents

Agonistas del receptor glucocorticoide sustituido de c20-c21.

Info

Publication number
MX2010007023A
MX2010007023A MX2010007023A MX2010007023A MX2010007023A MX 2010007023 A MX2010007023 A MX 2010007023A MX 2010007023 A MX2010007023 A MX 2010007023A MX 2010007023 A MX2010007023 A MX 2010007023A MX 2010007023 A MX2010007023 A MX 2010007023A
Authority
MX
Mexico
Prior art keywords
substituted
receptor agonists
compounds
glucocorticoid receptor
tautomers
Prior art date
Application number
MX2010007023A
Other languages
English (en)
Inventor
Robert G Aslanian
Daniel M Solomon
Kevin D Mccormick
John A Hey
Michael Y Berlin
John C Anthes
Purakkattle J Biju
Hongwu Wang
Yeon-Hee Lim
Rema Danielle Bitar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010007023A publication Critical patent/MX2010007023A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee compuestos de Fórmula (I), y sales, solvatos, ésteres, profármacos, tautómeros o isómeros farmacéuticamente aceptables de dichos compuestos, que tienen la estructura general (I); en donde L, R1, R2, R3, R4, R5, y R6 se seleccionan independientemente unos de otros y como se define en la presente; la presente invención también provee compuestos (y sales, solvatos, ésteres, profármacos, tautómeros e isómeros) de Fórmulas II, III, IV, V y VI, como se definen en la presente; se proveen además composiciones farmacéuticas, métodos de preparación, y métodos para usar dichos compuestos en el tratamiento y profilaxis de una amplia gama de enfermedades y condiciones inmunes, autoinmunes e inflamatorias.
MX2010007023A 2007-12-21 2008-12-18 Agonistas del receptor glucocorticoide sustituido de c20-c21. MX2010007023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1613507P 2007-12-21 2007-12-21
PCT/US2008/087300 WO2009085879A2 (en) 2007-12-21 2008-12-18 C20-c21 substituted glucocorticoid receptor agonists

Publications (1)

Publication Number Publication Date
MX2010007023A true MX2010007023A (es) 2010-09-30

Family

ID=40532554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007023A MX2010007023A (es) 2007-12-21 2008-12-18 Agonistas del receptor glucocorticoide sustituido de c20-c21.

Country Status (11)

Country Link
US (1) US8524697B2 (es)
EP (1) EP2245042A1 (es)
JP (1) JP2011507878A (es)
CN (1) CN101970452A (es)
AR (1) AR069804A1 (es)
CA (1) CA2710149A1 (es)
CL (1) CL2008003803A1 (es)
MX (1) MX2010007023A (es)
PE (1) PE20091525A1 (es)
TW (1) TW200944540A (es)
WO (1) WO2009085879A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003802A1 (es) * 2007-12-21 2010-02-19 Schering Corp Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple.
RU2420270C2 (ru) * 2009-07-20 2011-06-10 Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию Способ лечения рецидивирующего обструктивного бронхита у детей
WO2011029547A2 (en) * 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
CN103087137A (zh) * 2011-11-07 2013-05-08 天津金耀集团有限公司 一种21位为硫代烃基的糖皮质激素
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
WO2014115167A2 (en) * 2013-01-23 2014-07-31 Sphaera Pharma Pvt. Ltd. Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
GB201320091D0 (en) * 2013-11-14 2014-01-01 Univ Manchester Selective glucocorticoid receptor ligands
CN106714770B (zh) 2014-07-23 2024-04-19 斯法尔制药私人有限公司 羟基类固醇化合物、其中间体、制备方法、组合物及其用途
ES2877548T3 (es) 2016-06-02 2021-11-17 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
JP7330101B2 (ja) * 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
TW201825456A (zh) * 2016-11-24 2018-07-16 日商帝人製藥股份有限公司 硫醚化合物的製造方法
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
BR112020001360A2 (pt) 2017-07-24 2020-08-11 Regeneron Pharmaceuticals, Inc. anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto.
SG11202004151YA (en) 2017-11-07 2020-06-29 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
PH12020550779A1 (en) 2017-12-01 2021-04-19 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
SG11202004865SA (en) * 2017-12-01 2020-06-29 Abbvie Inc Anti-cd40 antibody drug conjugates
MX2020006994A (es) 2018-01-08 2020-11-06 Regeneron Pharma Esteroides y conjugados de anticuerpos de los mismos.
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
CN112851743A (zh) * 2019-11-27 2021-05-28 重庆华邦胜凯制药有限公司 一种氧化杂质的制备方法
CN112876531A (zh) * 2019-11-29 2021-06-01 重庆华邦胜凯制药有限公司 一种合成地奈德杂质的方法
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
TW202304464A (zh) 2021-03-23 2023-02-01 美商美國禮來大藥廠 新穎糖皮質素受體激動劑
TW202304462A (zh) 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
CN114702543B (zh) * 2022-04-19 2023-08-22 中国药科大学 Clascoterone衍生物或其可药用的盐及其制备方法和用途
CN115430392B (zh) * 2022-08-31 2024-04-16 江苏诺盟化工有限公司 一种苯偶酰的制备方法及专用文丘里喷射器

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1119082A (en) 1914-03-16 1914-12-01 George A Inman Protector-plate.
US3020275A (en) * 1960-06-07 1962-02-06 American Cyanamid Co 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same
GB1119082A (en) * 1966-07-11 1968-07-10 Lepetit Spa New steroids
DE1300940B (de) * 1966-10-13 1969-08-14 Hoechst Ag Verfahren zur Herstellung von Tetrahydropyranylaethern von Steroiden
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4861765A (en) 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
ZA866097B (en) * 1985-09-12 1988-03-30 Upjohn Co 20-and 21-amino steroids
JP2659279B2 (ja) * 1993-05-17 1997-09-30 アルコン ラボラトリーズ，インコーポレイテッド 眼科用抗炎症化合物
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
ES2317922T3 (es) 2000-08-05 2009-05-01 Glaxo Group Limited Derivados de beta-carbotioato 17, alfa-acrilcarboniloxiloxi androstano como agentes antiinflamatorios.
ES2249483T3 (es) * 2000-11-03 2006-04-01 The University Of Manchester Agonistas selectivos del receptor de glucocorticoides.
US20100209508A1 (en) * 2005-06-14 2010-08-19 Corus Pharma, Inc. Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction
CL2008003802A1 (es) 2007-12-21 2010-02-19 Schering Corp Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple.
US8916136B2 (en) * 2010-04-23 2014-12-23 Indian Institute Of Technology Bombay Glucose biosensor system coupled with an anti-inflammatory module and methods for using the same

Also Published As

Publication number Publication date
US20110182828A1 (en) 2011-07-28
JP2011507878A (ja) 2011-03-10
AR069804A1 (es) 2010-02-17
CN101970452A (zh) 2011-02-09
EP2245042A1 (en) 2010-11-03
CL2008003803A1 (es) 2010-02-19
CA2710149A1 (en) 2009-07-09
TW200944540A (en) 2009-11-01
US8524697B2 (en) 2013-09-03
PE20091525A1 (es) 2009-09-25
WO2009085879A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
MX2010007023A (es) Agonistas del receptor glucocorticoide sustituido de c20-c21.
TW200638933A (en) Compounds for inflammation and immune-related uses
WO2010142766A3 (en) Pyrimidine derivatives as zap-70 inhibitors
MX2007003342A (es) Compuestos para inflamacion y usos relacionados con trastornos inmunitarios.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
TW200637840A (en) Compounds for inflammation and immune-related uses
TW200716108A (en) Thiophene compounds for inflammation and immune-related uses
TW200744592A (en) Phenyl and pyridyl compounds for inflammation and immune-related uses
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
TW200806290A (en) Substituted biaryl compounds for inflammation and immune-related uses
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
MX2012004020A (es) Analogos de heterociclilo pirazolopirimidina como inhibidores de jak.
WO2009080638A3 (en) Sulfamides as zap-70 inhibitors
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
TW200806292A (en) Vinyl-phenyl derivatives for inflammation and immune-related uses
MX2010004705A (es) Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
GEP20146125B (en) Aminopyrimidines as syk inhibitors
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
WO2007084914A3 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
MX2010007024A (es) Tioéteres c-21 como agonista del receptor de glucocorticoides.
MX2012012328A (es) Compuestos pirazol como inhibidores de jak.
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: GLOBAL WATER GROUP, INCORPORATED

FA Abandonment or withdrawal